Going To The Dogs

Thursday, January 11, 2007 05:37 AM

In a week when the feds cracked down on some of those quick-loss diet companies with hefty fines for making false claims about their untested pills, it seemed just a bit odd that the FDA approved the first diet drug for dogs.

I can’t blame Pfizer Animal Health for going after this huge and growing market with Slentrol. There are about 62 million pet dogs in this country and more than 20 million are considered overweight or obese. I’d bet the very same owners of those 20 million dogs fit into those overweight and obese categories. Might be a good opportunity for Pfizer to cross-sell to the owners.

In a country where dog owners treat their animals as if they were their “babies”, it’s no surprise that their dogs are out-of-control eaters because most owners don’t train or control their dogs at all. Just watch an episode or two of the dog training show “Dog Whisperer” and see host Cesar Millan time and time again have to give owners basic dog training. His show should be mandatory for all new dog buyers...

Millan likes to say that dog owners must be pack leaders to their dogs. You would think the dog obesity problem could be avoided if dog owners exerted some control. The pack leaders should be able to ration the amount of food their dogs eat. They fill the dog bowls each day. It’s that simple.

Dog trainers such as Millan also recommend at least a 45-minute walk for a dog each day. If the human pack leader and his dog did that each day, a lot of the obesity problems in this country—for both humans and dogs—might just melt away. But that is unlikely to happen. So Pfizer’s drug for dogs will likely be a leader.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs